Jeri Hilleman jhilleman@si-bone.com & & +1 408-207-0700 | Ms. Hilleman is an experienced corporate director with over 15 years of board experience building on her career as CFO of several international public life sciences companies. As a director, Ms. Hilleman’s interests include defining growth strategies while developing accountable, performance-based organizations and nurturing leadership talent through partnership and mentorship. Ms. Hilleman is Chairperson of the Board of Omada Health, and currently serves on the boards of companies including NovoCure (NVCR), SI-Bone (SIBN) and HilleVax (HLVX) as well as private companies Omada Health and the Reiter Affiliated Companies, the farming arm of Driscoll’s Berries. Previously, she served on the boards of Xenoport (acquired), Cardiva (acquired) and Talis Biomedical. Ms. Hilleman has broad committee experience as well, serving on Audit (as Chair), Nominating & Governance, Compensation, Risk, Pricing, and M&A Committees. In addition, Ms. Hilleman serves as a merger compliance monitor for the FTC. As a global public company CFO, Ms. Hilleman was responsible for raising over one billion dollars in capital, including 5 successful initial public offerings, and executed numerous M&A transactions. She previously served as CFO of medical device, biotechnology and technology companies including Intersect ENT (acquired), Ocera Therapeutics (acquired), Amyris (AMRS) and Symyx Technologies (acquired). Ms. Hilleman graduated from Brown University and earned an M.B.A. from the Wharton School. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several Silicon Valley award programs for her contributions as a CFO and as a business leader.

Jeri Hilleman

Ms. Hilleman is an experienced corporate director with over 15 years of board experience building on her career...

Palo Alto, California, United States

*50 free lookup(s) per month.

No credit card required.

Jeri Hilleman’s Emails [email protected]

Jeri Hilleman’s Phone Numbers 1408207****

Social Media

Jeri Hilleman’s Location Palo Alto, California, United States

Jeri Hilleman’s Expertise Ms. Hilleman is an experienced corporate director with over 15 years of board experience building on her career as CFO of several international public life sciences companies. As a director, Ms. Hilleman’s interests include defining growth strategies while developing accountable, performance-based organizations and nurturing leadership talent through partnership and mentorship. Ms. Hilleman is Chairperson of the Board of Omada Health, and currently serves on the boards of companies including NovoCure (NVCR), SI-Bone (SIBN) and HilleVax (HLVX) as well as private companies Omada Health and the Reiter Affiliated Companies, the farming arm of Driscoll’s Berries. Previously, she served on the boards of Xenoport (acquired), Cardiva (acquired) and Talis Biomedical. Ms. Hilleman has broad committee experience as well, serving on Audit (as Chair), Nominating & Governance, Compensation, Risk, Pricing, and M&A Committees. In addition, Ms. Hilleman serves as a merger compliance monitor for the FTC. As a global public company CFO, Ms. Hilleman was responsible for raising over one billion dollars in capital, including 5 successful initial public offerings, and executed numerous M&A transactions. She previously served as CFO of medical device, biotechnology and technology companies including Intersect ENT (acquired), Ocera Therapeutics (acquired), Amyris (AMRS) and Symyx Technologies (acquired). Ms. Hilleman graduated from Brown University and earned an M.B.A. from the Wharton School. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several Silicon Valley award programs for her contributions as a CFO and as a business leader.

Jeri Hilleman’s Current Industry Amgen

Not the Jeri Hilleman you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Amgen

Federal Trade Commission (FTC) Monitor of Amgen acquisition of Horizon

Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) — Present

Medtronic

Federal Trade Commission (FTC) Monitor on Medtronic acquisition of Intersect ENT

Fri Apr 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) — Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Hillevax

Board Director, Audit Committee Chair, Comp Committee Member

Mon Mar 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) — Present

Si Bone

Member of Board of Directors, Audit Committee Chair, NCG Committee Member

Sun Dec 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) — Present

Cardiva

Member of Board of Directors and Audit Committee Chair

Sun Sep 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) — Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Reiter Affiliated Companies

Member of Board of Directors and Audit Committee Chair

Wed May 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) — Present

Omada Health

Chair of The Board of Directors

Mon Apr 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) — Present

Novocure

Member of Board of Directors and Audit Committee Chair

Sun Jul 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) — Present

Intersect

CFO

Sun Jun 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Dec 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Ocera Therapeutics

CFO

Sun Sep 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Jun 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Amyris

CFO

Tue Jan 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Jun 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Xenoport

Board of Directors, Audit Committee Chair

Thu Jan 01 2004 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Jul 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Symyx Technologies

CFO

Sun Jun 01 1997 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Jun 01 2007 00:00:00 GMT+0000 (Coordinated Universal Time)

Geron

VP Finance

Wed Jul 01 1992 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Jun 01 1997 00:00:00 GMT+0000 (Coordinated Universal Time)

Cytel

CFO

Sun Nov 01 1987 00:00:00 GMT+0000 (Coordinated Universal Time) — Wed Jul 01 1992 00:00:00 GMT+0000 (Coordinated Universal Time)

Skills

Languages

FAQ About Jeri Hilleman

Jeri Hilleman is located at
Palo Alto, California, United States

Jeri Hilleman is a
Ms. Hilleman is an experienced corporate director with over 15 years of board experience building on her career as CFO of several international public life sciences companies. As a director, Ms. Hilleman’s interests include defining growth strategies while developing accountable, performance-based organizations and nurturing leadership talent through partnership and mentorship. Ms. Hilleman is Chairperson of the Board of Omada Health, and currently serves on the boards of companies including NovoCure (NVCR), SI-Bone (SIBN) and HilleVax (HLVX) as well as private companies Omada Health and the Reiter Affiliated Companies, the farming arm of Driscoll’s Berries. Previously, she served on the boards of Xenoport (acquired), Cardiva (acquired) and Talis Biomedical. Ms. Hilleman has broad committee experience as well, serving on Audit (as Chair), Nominating & Governance, Compensation, Risk, Pricing, and M&A Committees. In addition, Ms. Hilleman serves as a merger compliance monitor for the FTC. As a global public company CFO, Ms. Hilleman was responsible for raising over one billion dollars in capital, including 5 successful initial public offerings, and executed numerous M&A transactions. She previously served as CFO of medical device, biotechnology and technology companies including Intersect ENT (acquired), Ocera Therapeutics (acquired), Amyris (AMRS) and Symyx Technologies (acquired). Ms. Hilleman graduated from Brown University and earned an M.B.A. from the Wharton School. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several Silicon Valley award programs for her contributions as a CFO and as a business leader. Amgen

Jeri Hilleman currently works in the
Amgen

Jeri Hilleman specializes in
Ms. Hilleman is an experienced corporate director with over 15 years of board experience building on her career as CFO of several international public life sciences companies. As a director, Ms. Hilleman’s interests include defining growth strategies while developing accountable, performance-based organizations and nurturing leadership talent through partnership and mentorship. Ms. Hilleman is Chairperson of the Board of Omada Health, and currently serves on the boards of companies including NovoCure (NVCR), SI-Bone (SIBN) and HilleVax (HLVX) as well as private companies Omada Health and the Reiter Affiliated Companies, the farming arm of Driscoll’s Berries. Previously, she served on the boards of Xenoport (acquired), Cardiva (acquired) and Talis Biomedical. Ms. Hilleman has broad committee experience as well, serving on Audit (as Chair), Nominating & Governance, Compensation, Risk, Pricing, and M&A Committees. In addition, Ms. Hilleman serves as a merger compliance monitor for the FTC. As a global public company CFO, Ms. Hilleman was responsible for raising over one billion dollars in capital, including 5 successful initial public offerings, and executed numerous M&A transactions. She previously served as CFO of medical device, biotechnology and technology companies including Intersect ENT (acquired), Ocera Therapeutics (acquired), Amyris (AMRS) and Symyx Technologies (acquired). Ms. Hilleman graduated from Brown University and earned an M.B.A. from the Wharton School. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several Silicon Valley award programs for her contributions as a CFO and as a business leader.

Jeri Hilleman speaks the following languages:
No languages available.

Jeri Hilleman has prior experience in the following industries:
Medtronic , Cardiva , Intersect , Ocera Therapeutics , Amyris , Xenoport , Symyx Technologies , Geron , Cytel

Jeri Hilleman has the following professional experience:
Amgen , Medtronic , Hillevax , Si Bone , Cardiva , Reiter Affiliated Companies , Omada Health , Novocure , Intersect , Ocera Therapeutics , Amyris , Xenoport , Symyx Technologies , Geron , Cytel .